Sanofi, Regeneron expand partnership in deal worth up to $8 billion

Sanofi and Regeneron have expanded their existing partnership through a new agreement valued at up to $8 billion. Under this deal, Sanofi will provide payments to Regeneron to incorporate additional new antibodies into the Dupixent partnership. This strategic expansion aims to broaden the scope of their collaboration by adding these specific therapeutic agents to the current framework, strengthening the commercial and developmental ties between the two pharmaceutical companies regarding their shared antibody research and product pipeline.